165 related articles for article (PubMed ID: 33682120)
1. Population-level changes in outcomes and Medicare cost following the introduction of new cancer therapies.
Youn B; Wilson IB; Mor V; Trikalinos NA; Dahabreh IJ
Health Serv Res; 2021 Jun; 56(3):486-496. PubMed ID: 33682120
[TBL] [Abstract][Full Text] [Related]
2. Antineoplastic Treatment of Advanced-Stage Non-Small-Cell Lung Cancer: Treatment, Survival, and Spending (2000 to 2011).
Bradley CJ; Yabroff KR; Mariotto AB; Zeruto C; Tran Q; Warren JL
J Clin Oncol; 2017 Feb; 35(5):529-535. PubMed ID: 28045621
[TBL] [Abstract][Full Text] [Related]
3. Real-World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated With Second-Line Therapies for Medicare Patients With Advanced Non-Small-Cell Lung Cancer.
Arunachalam A; Li H; Bittoni MA; Camacho R; Cao X; Zhong Y; Lubiniecki GM; Carbone DP
Clin Lung Cancer; 2018 Sep; 19(5):e783-e799. PubMed ID: 29983370
[TBL] [Abstract][Full Text] [Related]
4. Factors Associated With Use of High-Cost Agents for the Treatment of Metastatic Non-Small Cell Lung Cancer.
Bradley CJ; Eguchi M; Perraillon MC
J Natl Cancer Inst; 2020 Aug; 112(8):802-809. PubMed ID: 31710664
[TBL] [Abstract][Full Text] [Related]
5. Real-World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated With First-line Therapies for Medicare Patients 65 Years and Older With Advanced Non-small-cell Lung Cancer: A Retrospective Study.
Bittoni MA; Arunachalam A; Li H; Camacho R; He J; Zhong Y; Lubiniecki GM; Carbone DP
Clin Lung Cancer; 2018 Sep; 19(5):e629-e645. PubMed ID: 29885945
[TBL] [Abstract][Full Text] [Related]
6. Greater Spending Associated with Improved Survival for Some Cancers in OCM-Defined Episodes.
Baumgardner J; Shahabi A; Linthicum M; Vine S; Zacker C; Lakdawalla D
J Manag Care Spec Pharm; 2018 Jun; 24(6):504-513. PubMed ID: 29799330
[TBL] [Abstract][Full Text] [Related]
7. Neutropenia-related costs in patients treated with first-line chemotherapy for advanced non-small cell lung cancer.
Stokes ME; Muehlenbein CE; Marciniak MD; Faries DE; Motabar S; Gillespie TW; Lipscomb J; Knopf KB; Buesching DP
J Manag Care Pharm; 2009 Oct; 15(8):669-82. PubMed ID: 19803556
[TBL] [Abstract][Full Text] [Related]
8. Medicare Spending for Breast, Prostate, Lung, and Colorectal Cancer Patients in the Year of Diagnosis and Year of Death.
Chen CT; Li L; Brooks G; Hassett M; Schrag D
Health Serv Res; 2018 Aug; 53(4):2118-2132. PubMed ID: 28748564
[TBL] [Abstract][Full Text] [Related]
9. Patterns of care for older patients with stage IV non-small cell lung cancer in the immunotherapy era.
Kehl KL; Hassett MJ; Schrag D
Cancer Med; 2020 Mar; 9(6):2019-2029. PubMed ID: 31989786
[TBL] [Abstract][Full Text] [Related]
10. Real-world effectiveness of systemic agents approved for advanced non-small cell lung cancer: a SEER-Medicare analysis.
Owonikoko TK; Ragin C; Chen Z; Kim S; Behera M; Brandes JC; Saba NF; Pentz R; Ramalingam SS; Khuri FR
Oncologist; 2013; 18(5):600-10. PubMed ID: 23635558
[TBL] [Abstract][Full Text] [Related]
11. Carboplatin and paclitaxel with vs without bevacizumab in older patients with advanced non-small cell lung cancer.
Zhu J; Sharma DB; Gray SW; Chen AB; Weeks JC; Schrag D
JAMA; 2012 Apr; 307(15):1593-601. PubMed ID: 22511687
[TBL] [Abstract][Full Text] [Related]
12. Regional variation in spending and survival for older adults with advanced cancer.
Brooks GA; Li L; Sharma DB; Weeks JC; Hassett MJ; Yabroff KR; Schrag D
J Natl Cancer Inst; 2013 May; 105(9):634-42. PubMed ID: 23482657
[TBL] [Abstract][Full Text] [Related]
13. Hospital Variation in Spending for Lung Cancer Resection in Medicare Beneficiaries.
Jean RA; Bongiovanni T; Soulos PR; Chiu AS; Herrin J; Kim N; Xu X; Kim AW; Gross CP
Ann Thorac Surg; 2019 Dec; 108(6):1710-1716. PubMed ID: 31400321
[TBL] [Abstract][Full Text] [Related]
14. An economic analysis of sublobar resection versus thermal ablation for early-stage non-small-cell lung cancer.
Kwan SW; Mortell KE; Hippe DS; Brunner MC
J Vasc Interv Radiol; 2014 Oct; 25(10):1558-64; quiz 1565. PubMed ID: 25130308
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of pembrolizumab for advanced non-small cell lung cancer patients with varying comorbidity burden.
Criss SD; Palazzo L; Watson TR; Paquette AM; Sigel K; Wisnivesky J; Kong CY
PLoS One; 2020; 15(1):e0228288. PubMed ID: 31995619
[TBL] [Abstract][Full Text] [Related]
16. Three-year follow-up results from phase II studies of nivolumab in Japanese patients with previously treated advanced non-small cell lung cancer: Pooled analysis of ONO-4538-05 and ONO-4538-06 studies.
Horinouchi H; Nishio M; Hida T; Nakagawa K; Sakai H; Nogami N; Atagi S; Takahashi T; Saka H; Takenoyama M; Katakami N; Tanaka H; Takeda K; Satouchi M; Isobe H; Maemondo M; Goto K; Hirashima T; Minato K; Sumiyoshi N; Tamura T
Cancer Med; 2019 Sep; 8(11):5183-5193. PubMed ID: 31353840
[TBL] [Abstract][Full Text] [Related]
17. An Exploratory Analysis of Real-World End Points for Assessing Outcomes Among Immunotherapy-Treated Patients With Advanced Non-Small-Cell Lung Cancer.
Stewart M; Norden AD; Dreyer N; Henk HJ; Abernethy AP; Chrischilles E; Kushi L; Mansfield AS; Khozin S; Sharon E; Arunajadai S; Carnahan R; Christian JB; Miksad RA; Sakoda LC; Torres AZ; Valice E; Allen J
JCO Clin Cancer Inform; 2019 Jul; 3():1-15. PubMed ID: 31335166
[TBL] [Abstract][Full Text] [Related]
18. Association Between First-Line Immune Checkpoint Inhibition and Survival for Medicare-Insured Patients With Advanced Non-Small Cell Lung Cancer.
Kehl KL; Greenwald S; Chamoun NG; Manberg PJ; Schrag D
JAMA Netw Open; 2021 May; 4(5):e2111113. PubMed ID: 34019086
[TBL] [Abstract][Full Text] [Related]
19. Treatment patterns and cost-effectiveness of first line treatment of advanced non-squamous non-small cell lung cancer in Medicare patients.
Gilden DM; Kubisiak JM; Pohl GM; Ball DE; Gilden DE; John WJ; Wetmore S; Winfree KB
J Med Econ; 2017 Feb; 20(2):151-161. PubMed ID: 27574722
[TBL] [Abstract][Full Text] [Related]
20. Impact of Hospice on Spending and Utilization Among Patients With Lung Cancer in Medicare.
Kalidindi Y; Segel J; Jung J
Am J Hosp Palliat Care; 2020 Apr; 37(4):286-293. PubMed ID: 31564110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
